Amylyx Pharmaceuticals, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value
Amylyx Pharmaceuticals, Inc. (AMLX) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value of $7.90 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures
us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1 · last filed 2026-08-06
- Amylyx Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, options, vested in period, fair value for the quarter ending 2026-06-30 was $3.30M, a 15.38% decline year-over-year.
- Amylyx Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, options, vested in period, fair value for the quarter ending 2026-03-31 was $4.60M, a 31.34% decline year-over-year.
- Amylyx Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, options, vested in period, fair value for the quarter ending 2025-12-31 was $3.90M, a 9.30% decline year-over-year.
- Amylyx Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, options, vested in period, fair value for the quarter ending 2025-09-30 was $4.00M, a 11.11% decline year-over-year.
- Amylyx Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, options, vested in period, fair value for fiscal 2025 was $18.50M, a 43.08% decline from fiscal 2024.
- Amylyx Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, options, vested in period, fair value for fiscal 2024 was $32.50M, a 4.17% increase from fiscal 2023.
- Amylyx Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, options, vested in period, fair value for fiscal 2023 was $31.20M, a 254.55% increase from fiscal 2022.
- Amylyx Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, options, vested in period, fair value for fiscal 2022 was $8.80M, a 576.92% increase from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value 12 month |
|---|---|---|---|---|
| 2026-06-30 | $3.30M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $7.90M 10-Q · filed 2026-08-06 | $11.80M derived: sum of 3 quarters · filed 2026-08-06 | $15.80M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $4.60M 10-Q · filed 2026-05-07 | $8.50M derived: sum of 2 quarters · filed 2026-05-07 | $12.50M derived: sum of 3 quarters · filed 2026-05-07 | $16.40M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $3.90M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-03 | $7.90M derived: sum of 2 quarters · filed 2026-03-03 | $11.80M derived: sum of 3 quarters · filed 2026-08-06 | $18.50M 10-K · filed 2026-03-03 |
| 2025-09-30 | $4.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $7.90M derived: sum of 2 quarters · filed 2026-08-06 | $14.60M 10-Q · filed 2025-11-06 | $18.90M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $3.90M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $10.60M 10-Q · filed 2026-08-06 | $14.90M derived: sum of 3 quarters · filed 2026-08-06 | $19.40M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $6.70M 10-Q · filed 2026-05-07 | $11.00M derived: sum of 2 quarters · filed 2026-05-07 | $15.50M derived: sum of 3 quarters · filed 2026-05-07 | $24.30M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $4.30M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-03 | $8.80M derived: sum of 2 quarters · filed 2026-03-03 | $17.60M derived: sum of 3 quarters · filed 2026-03-03 | $32.50M 10-K · filed 2026-03-03 |
| 2024-09-30 | $4.50M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $13.30M derived: sum of 2 quarters · filed 2025-11-06 | $28.20M 10-Q · filed 2025-11-06 | $34.60M derived: sum of 4 quarters · filed 2025-11-06 |
| 2024-06-30 | $8.80M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | $23.70M 10-Q · filed 2025-08-07 | $30.10M derived: sum of 3 quarters · filed 2025-08-07 | $35.00M derived: sum of 4 quarters · filed 2025-08-07 |
| 2024-03-31 | $14.90M 10-Q · filed 2025-05-08 | $21.30M derived: sum of 2 quarters · filed 2025-05-08 | $26.20M derived: sum of 3 quarters · filed 2025-05-08 | $31.40M derived: sum of 4 quarters · filed 2025-05-08 |
| 2023-12-31 | $6.40M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-04 | $11.30M derived: sum of 2 quarters · filed 2025-03-04 | $16.50M derived: sum of 3 quarters · filed 2025-03-04 | $31.20M 10-K · filed 2025-03-04 |
| 2023-09-30 | $4.90M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | $10.10M derived: sum of 2 quarters · filed 2024-11-07 | $24.80M 10-Q · filed 2024-11-07 | $28.50M derived: sum of 4 quarters · filed 2024-11-07 |
| 2023-06-30 | $5.20M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | $19.90M 10-Q · filed 2024-08-08 | $23.60M derived: sum of 3 quarters · filed 2024-08-08 | $25.50M derived: sum of 4 quarters · filed 2024-08-08 |
| 2023-03-31 | $14.70M 10-Q · filed 2024-05-09 | $18.40M derived: sum of 2 quarters · filed 2024-05-09 | $20.30M derived: sum of 3 quarters · filed 2024-05-09 | $21.70M derived: sum of 4 quarters · filed 2024-05-09 |
| 2022-12-31 | $3.70M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-22 | $5.60M derived: sum of 2 quarters · filed 2024-02-22 | $7.00M derived: sum of 3 quarters · filed 2024-02-22 | $8.80M 10-K · filed 2024-02-22 |
| 2022-09-30 | $1.90M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | $3.30M derived: sum of 2 quarters · filed 2023-11-09 | $5.10M 10-Q · filed 2023-11-09 | $5.70M derived: sum of 4 quarters · filed 2024-02-22 |
| 2022-06-30 | $1.40M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10 | $3.20M 10-Q · filed 2023-08-10 | $3.80M derived: sum of 3 quarters · filed 2024-02-22 | $4.10M derived: sum of 4 quarters · filed 2024-02-22 |
| 2022-03-31 | $1.80M 10-Q · filed 2023-05-11 | $2.40M derived: sum of 2 quarters · filed 2024-02-22 | $2.70M derived: sum of 3 quarters · filed 2024-02-22 | $2.90M derived: sum of 4 quarters · filed 2024-02-22 |
| 2021-12-31 | $600.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-22 | $900.00K derived: sum of 2 quarters · filed 2024-02-22 | $1.10M derived: sum of 3 quarters · filed 2024-02-22 | $1.30M 10-K · filed 2024-02-22 |
| 2021-09-30 | $300.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-10 | $500.00K derived: sum of 2 quarters · filed 2022-11-10 | $700.00K 10-Q · filed 2022-11-10 | |
| 2021-06-30 | $200.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-11 | $400.00K 10-Q · filed 2022-08-11 | ||
| 2021-03-31 | $200.00K 10-Q · filed 2022-05-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |
| Arcus Biosciences, Inc. (RCUS) | United States | $3.188B | -8.52 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| Dyne Therapeutics, Inc. (DYN) | United States | $3.084B | -7.09 |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 | |
| PRECIGEN, INC. (PGEN) | United States | $2.757B | -12.94 |